Viking Therapeutics, Inc.

The Viking Therapeutics 2021 First Quarter Financial Results Conference Call. At this time, all participants are in a listen-only mode. Following management's prepared remarks, we will hold a Q&A session. To ask a question at that time, please press the star key followed by 1 on your touchtone phone. If anyone has difficulty hearing the conference, please press star 0 for operator assistance. As a reminder, this conference call is being recorded today, April 28th, 2021. I would now like to turn the conference over to Vikings Manager of Investor Relations, Stephanie Diaz. Please go ahead, Stephanie.

Hello, and thank you all for participating in today's call. Joining me today is Brian Land, Vikings President and CEO, and Greg Santee, Vikings CFO. Before we begin, I'd like to caution that comments made during this conference call today, April 28th, 2021, will contain forward-looking statements under the Safe Harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including statements about Viking's expectations regarding its development activities, timelines, and milestones. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially and adversely, and reported results should not be considered as an indication of future performance. These forward-looking statements speak only as of today's date, and the company undertakes no obligation to revise or update any statement made today. I encourage you to review all of the company's filings with the Securities and Exchange Commission concerning these and other matters. I'll now turn the call over to Brian Land for his initial comments.

Thanks, Stephanie, and thanks to everyone listening on the webcast or by phone. Today, we'll provide an overview of our first quarter 2021 financial results, as well as an update on recent progress and developments with our pipeline programs and operations. During the first quarter, we continued to build on the progress made over the past year with both of our thyroid hormone beta receptor agonist programs. With our lead program, VK2809, for the treatment of non-alcoholics, diatohepatitis, and fibrosis, we continued enrolling patients in our Phase IIb voyage study and added new clinical sites in both the U.S. and outside the U.S., During the first quarter, we also continued enrollment in a Phase I trial evaluating our second thyroid hormone beta receptor agonist, VK0214, for the treatment of X-linked adrenal leukodystrophy, or XALD. This trial is advancing well, and we are nearing completion of the study's initial phase, evaluating VK0214 in healthy volunteers. I'll provide additional detail on our development activities after we review our first quarter financial results. For that, I'll turn the call over to Greg Zanti, Viking CFO.